ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM | N213388 | ABBVIE INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AbbVie Inc. v. Teva Pharmaceuticals, Inc. et al 4 patentsANDA 217650elagolix sodium (eq. 300 mg base), estradiol (1 mg), and norethindrone acetate (0.5 mg) | D. Del. | 2023-11-07 | Terminated 2024-01-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).